Indications of Lenalidomide

Multiple Myeloma

Revlimid in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM).

Revlimid is indicated for maintenance therapy in adult patients with multiple myeloma following autologous hematopoietic stem cell transplantation (auto-HSCT).

Myelodysplastic Syndromes

Revlimid is indicated for the treatment of adult patients with transfusion-dependent anemia due to low-risk or intermediate-1 myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality (with or without other cytogenetic abnormalities).

Mantle Cell Lymphoma

Revlimid is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

Follicular Lymphoma

Revlimid in combination with rituximab products is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).

Marginal Zone Lymphoma

Revlimid in combination with rituximab products is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).

Usage Restrictions

Revlimid is not indicated for and is not recommended for the treatment of patients with CLL outside of controlled clinical trials.

FDA，2023.03